CRIS Current Research Information System

SCOTLANDI, KATIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.276
EU - Europa 2.502
AS - Asia 1.274
AF - Africa 138
SA - Sud America 11
OC - Oceania 4
Totale 7.205
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.254
IT - Italia 675
GB - Regno Unito 515
DE - Germania 396
VN - Vietnam 370
CN - Cina 364
SG - Singapore 334
SE - Svezia 305
IN - India 122
IE - Irlanda 112
CH - Svizzera 105
RU - Federazione Russa 96
FR - Francia 72
UA - Ucraina 59
TG - Togo 53
ZA - Sudafrica 40
BG - Bulgaria 38
EE - Estonia 37
CI - Costa d'Avorio 33
JO - Giordania 28
FI - Finlandia 26
NL - Olanda 20
CA - Canada 19
BE - Belgio 18
ID - Indonesia 18
JP - Giappone 11
NG - Nigeria 9
ES - Italia 8
CL - Cile 6
HK - Hong Kong 6
PK - Pakistan 5
TR - Turchia 5
AU - Australia 4
PL - Polonia 4
DK - Danimarca 3
GR - Grecia 3
IR - Iran 3
KR - Corea 3
SC - Seychelles 3
AR - Argentina 2
BR - Brasile 2
HR - Croazia 2
MX - Messico 2
RO - Romania 2
TH - Thailandia 2
AT - Austria 1
CR - Costa Rica 1
HU - Ungheria 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
PE - Perù 1
PT - Portogallo 1
SI - Slovenia 1
Totale 7.205
Salva come PNG Salva come JPEG
Città #
Southend 460
Fairfield 391
Chandler 370
Singapore 297
Ashburn 245
Dong Ket 210
Woodbridge 194
Ann Arbor 183
Wilmington 181
Houston 165
Seattle 165
Bologna 140
Santa Clara 140
Cambridge 139
Princeton 124
Dublin 112
Frankfurt am Main 101
Bern 100
Boardman 86
Lomé 53
Nanjing 49
Westminster 43
Bremen 41
Berlin 39
Turin 39
Sofia 38
Padova 36
Florence 35
Abidjan 33
New York 29
Amman 28
Beijing 28
Jacksonville 28
San Diego 28
Saint Petersburg 26
Milan 24
Jinan 23
Helsinki 22
Redmond 22
Jakarta 18
Brussels 17
Catanzaro 17
Hebei 17
Los Angeles 17
Changsha 15
Guangzhou 15
Rome 15
Des Moines 14
Falls Church 14
Shenyang 14
Shanghai 13
Medford 12
Redwood City 12
Dearborn 11
Nanchang 11
Phoenix 11
Jiaxing 10
London 10
Mülheim 10
Parma 10
Tokyo 10
Verona 10
Crocetta 9
Tianjin 9
Bühl 8
Falkenstein 8
Kuban 8
Paris 8
Abeokuta 7
Francavilla Al Mare 7
Shenzhen 7
Amsterdam 6
Boydton 6
Fuzhou 6
Hangzhou 6
Hyderabad 6
Ottawa 6
Salamanca 6
San Pietro In Casale 6
Wuhan 6
Zhengzhou 6
Hong Kong 5
Ravenna 5
Reggio Emilia 5
Siderno 5
Taizhou 5
Toronto 5
Dallas 4
Forlì 4
Kunming 4
Leawood 4
Modena 4
Ningbo 4
Taiyuan 4
Carrara 3
Chengdu 3
Chongqing 3
Codigoro 3
Haikou 3
Lappeenranta 3
Totale 4.977
Salva come PNG Salva come JPEG
Nome #
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 227
Altered modulation of lamin A/C-HDAC2 interaction and p21 expression during oxidative stress response in HGPS 197
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma 174
Cell growth inhibition and apoptotic effect of the rexinoid 6-OH-11-O-hydroxyphenantrene on human osteosarcoma and mesenchymal stem cells. 161
CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. 161
CD99 polymorphisms significantly influence the probability to develop Ewing sarcoma in earlier age and patient disease progression 158
Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. 157
CD99 Acts as an Oncosuppressor in Osteosarcoma. 157
Characterization of human mesenchymal stem cells from Ewing sarcoma patients. Pathogenetic implications 148
Biological indicators of prognosis in Ewing’s sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). 148
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy 147
An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. 143
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. 142
New Insights into the Hepcidin-Ferroportin Axis and Iron Homeostasis in iPSC-Derived Cardiomyocytes from Friedreich's Ataxia Patient 137
Does MGMT (O6-methylguanine–DNA methyltransferase) have a role in metastatic Ewing sarcoma (ES) patients (pts) undergoing temozolomide (TMZ) and irinotecan (IRI)? 133
CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2. 132
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1 132
CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity 130
A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function 130
Targeting CD99 compromises the oncogenic effects of the chimera EWS-FLI1 by inducing re-expression of zyxin and inhibition of Gli1 activity 128
Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients 127
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. 126
ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity 126
Insulin-like growth factor 2 mRNA-binding protein 3 is a novel post-transcriptional regulator of Ewing sarcoma malignancy 125
Apoptotic genes as potential markers of metastatic phenotype in human osteosarcoma cell lines. 125
Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling 122
Abstract 3201: Insulin-like growth factor 2 (IGF-2) mRNA binding protein 3 predicts poor prognosis and promotes cell proliferation in Ewing sarcoma 122
Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma 122
Exosomes from CD99-deprived Ewing sarcoma cells reverse tumor malignancy by inhibiting cell migration and promoting neural differentiation 120
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 115
Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing’s sarcoma 113
Lamin A and prelamin A counteract invasiveness of osteosarcoma cells 113
Prelamin A-mediated recruitment of SUN1 to the nuclear envelope directs nuclear positioning in human muscle. 112
Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells. 111
Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing’s sarcoma. 111
Immune-infiltrate characterization in localized osteosarcoma patients treated within protocol ISG-OS1. 110
Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma 110
SELNET clinical practice guidelines for soft tissue sarcoma and GIST 110
Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression 104
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 104
Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types 102
NVE-BEZ235 as a new therapeutic option for sarcomas. 95
Insulin-like growth factor binding protein 3 as an anti-cancer molecule in Ewing's sarcoma. 94
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 94
Lamin A acts a tumor suppressor in Ewing sarcoma promoting neural differentiation and reducing cell migration and invasion 92
PD1 and PDL1 expression, tumoral microenvironment (TME) characterization and clinical implication in localized osteosarcoma 90
Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. 87
Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Modulates Aggressiveness of Ewing Sarcoma by Regulating the CD164-CXCR4 Axis 86
Irinotecan and temozolomide upfront and in relapsed Ewing sarcoma: A translational study on MGMT (O6-methylguanine–DNA methyltransferase) and ABCG2 (MGMTLiberati) 84
Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells 83
miRNA signature predicts survival of Ewing’s sarcoma patients and miR34a directly influences cell chemosensitivity and malignancy 79
Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33 75
Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma 75
Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade 72
null 70
Gene amplification is associated with methotrexate resistance in human osteosarcoma cell lines 69
Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells 62
Polymorphic variants of IGF2BP3 and SENCR have an impact on predisposition and/or progression of Ewing sarcoma 61
Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research 60
ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis 60
Identification of candidate genes involved in the reversal of malignant phenotype of osteosarcoma cells transfected with the liver/bone/kidney alkaline phosphatase gene 60
Zyxin in Ewing sarcoma: a novel role as mediator between CD99 and EWS-FLI1 56
The role of zyxin as a mediator between CD99 and EWS-FLI1 55
Correction to: ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis 51
SELNET clinical practice guidelines for bone sarcoma 44
Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study 40
IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience 39
CD99 contributes to the EWS::FLI1 transcriptome by specifically affecting FOXM1-targets involved in the G2/M cell cycle phase, thus influencing the Ewing sarcoma genetic landscape 36
Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2) 35
Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma 34
Corrigendum to “SELNET clinical practice guidelines for bone sarcoma” Critical reviews in oncology/hematology, vol. 174 (2022), 1–10 (Critical Reviews in Oncology / Hematology (2022) 174, (S1040842822001093), (10.1016/j.critrevonc.2022.103685)) 25
null 3
Totale 7.438
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.898
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.898
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020844 0 0 0 0 0 0 196 210 199 102 65 72
2020/20211.005 130 51 16 44 24 40 8 61 91 49 41 450
2021/20221.343 86 41 82 69 107 62 46 96 62 146 300 246
2022/20231.750 143 207 89 242 102 119 72 90 291 55 177 163
2023/2024482 32 87 44 58 31 84 34 32 18 25 11 26
2024/2025960 104 217 139 136 249 101 14 0 0 0 0 0
Totale 7.438